Swedish biotech company BioInvent International AB (STO:BINV) announced on Friday that the US Food and Drug Administration (FDA) has granted Fast Track designation to its first-in-class anti-TNFR2 antibody BI-1808, in combination with pembrolizumab, for the treatment of ovarian cancer.
Interim Phase 2a data presented at ASCO 2026 showed BI-1808 plus pembrolizumab achieved a 24% confirmed overall response rate and a 56% disease control rate in heavily pretreated patients with advanced platinum-resistant ovarian cancer.
The company said the combination demonstrated durable benefit across high-grade serous and clear cell subtypes, with several responses ongoing beyond 10 months and a preliminary median progression-free survival of 10.3 months.
Cohort expansion is underway with a focus on high-grade serous and clear cell ovarian cancer, and another data readout is expected in the second half of 2026.
Zai Lab's zoci receives FDA orphan designation for neuroendocrine carcinomas
Biocon launches Yesafili biosimilar in US ophthalmology market
Ractigen Therapeutics IND application for RAG-1C receives FDA clearance
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
European Commission approves RINVOQ for severe alopecia areata
Incyte's Opzelura approved in European Union for moderate atopic dermatitis
RTW Biotech portfolio company Yarrow Bioscience completes merger
Lupin's Diazepam Injection, USP receives US approval
Auxilium Health changes name to Aeris Biosciences
Saol Therapeutics' SL1009 (DCA) resubmission accepted by FDA